TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity
Authors
Keywords
-
Journal
OncoImmunology
Volume 9, Issue 1, Pages 1681869
Publisher
Informa UK Limited
Online
2019-11-05
DOI
10.1080/2162402x.2019.1681869
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- IL2/anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation
- (2019) Pamela Caudana et al. Cancer Immunology Research
- Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
- (2019) Cornelia Hutmacher et al. Cancer Immunology Research
- Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses
- (2018) Ken Garber NATURE BIOTECHNOLOGY
- A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism
- (2018) Eleonora Trotta et al. NATURE MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
- (2018) Laurence Zitvogel et al. SCIENCE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Unknown
- (2017) IMMUNOLOGICAL REVIEWS
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
- (2017) Deborah Charych et al. PLoS One
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- An essential role for the IL-2 receptor in Treg cell function
- (2016) Takatoshi Chinen et al. NATURE IMMUNOLOGY
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Cancer immunotherapy targeting neoantigens
- (2016) Yong-Chen Lu et al. SEMINARS IN IMMUNOLOGY
- Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
- (2015) Jamie B. Spangler et al. IMMUNITY
- Tissue-Specific Distribution of iNKT Cells Impacts Their Cytokine Response
- (2015) You Jeong Lee et al. IMMUNITY
- Interleukin-2: Biology, Design and Application
- (2015) Natalia Arenas-Ramirez et al. TRENDS IN IMMUNOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- Markers of Nonselective and Specific NK Cell Activation
- (2013) L. A. Fogel et al. JOURNAL OF IMMUNOLOGY
- Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies
- (2013) Conor Fields et al. Nature Protocols
- Exploiting the Mutanome for Tumor Vaccination
- (2012) J. C. Castle et al. CANCER RESEARCH
- Cutting Edge: A Novel Mechanism Bridging Innate and Adaptive Immunity: IL-12 Induction of CD25 To Form High-Affinity IL-2 Receptors on NK Cells
- (2012) S.-H. Lee et al. JOURNAL OF IMMUNOLOGY
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15R complexes
- (2010) K. G. Elpek et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Maturation of mouse NK cells is a 4-stage developmental program
- (2009) L. Chiossone et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started